SML2017

Compound C108

≥98% (HPLC)

• Sinonimo/i: 2-Hydroxy-2-[1-(2-hydroxyphenyl)ethylidene]hydrazide-benzoic acid, 2-Hydroxy-N′-[1-(2-hydroxyphenyl)ethylidene]benzohydrazide
• Formula empirica (notazione di Hill): C₁₅H₁₄N₂O₃
• Numero CAS: 15533-09-2
• Peso molecolare: 270.28
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder

Proprietà

• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• shipped in: ambient
• storage temp.: −20°C
• SMILES string: OC1=C(C=CC=C1)C(C)=NNC(C2=C(C=CC=C2)O)=O

Descrizione

Biochem/physiol Actions

C108 is a small molecule that exhibits cancer-selective cytotoxicity (Viability = 100%/MCF-10A vs. 50%/BT-474, 67%/4T1, 70%/MDA-MB-231 & MDA-MB-453 post 48 h 1 μM C108 treatment) and synergizes with low dose paclitaxel in reducing ALDH-positive tumor-initiating cells (TIC poulation = 56.6%/control, 60.6%/0.1 μM paclitaxel alone, 47.4%/1 μM C108 alone, 7.3%/combined treatment for 24 h in BT474 breast cancer cultures) by targeting stress granule-associated protein G3BP2 (GAP SH3 domain-binding protein 2). Likewise, C108 pretreatment prior to xenografting greatly reduces BT-474 tumor-initiating frequency (from 1/175 to 1/1103 by limiting dilution xenograft assays) in mice in vivo. G3BP2 is reported to bind and stabilize SART3 mRNA, thereby indirectly regulating the core pluripotency transcription factors Oct-4 and Nanog critically involved in ESC self-renewal and breast tumor initiation.

G3BP2 inhibitor that exhibits cancer-selective toxicity and synergizes with low dose paclitaxel against tumor-initiating cell (TIC) population in breast cancer cultures.

Informazioni sulla sicurezza

• pictograms: GHS07
• signalword: Warning
• hcodes: H315,H319
• pcodes: P264 - P280 - P302 + P352 - P305 + P351 + P338 - P332 + P313 - P337 + P313
• Hazard Classifications: Eye Irrit. 2 - Skin Irrit. 2
• Classe di stoccaggio: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable